Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LD-ITUK in Severe Aneurysmal Subarachnoid Hemorrhage
NCT06284642Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Mar 2024
- Primary completion
- Jun 2027
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of urokinase in aneurysmal subarachnoid hemorrhage (SAH) (2 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Modified Rankin Scale at 180 days. Started Mar 2024; status: recruiting.
02
Drugs
urokinase
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT06284642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284642.